News
Stories and articles featuring PCI, our partners, and Penn-affiliated spinout companies
Stories and articles featuring PCI, our partners, and Penn-affiliated spinout companies
Gemma Biotherapeutics was co-founded in 2024 by James M. Wilson, MD, PhD, the Rose H. Weiss Orphan Disease Center Director's Professor in Penn Medicine.
HiveBio has selected its inaugural cohort of underrepresented biotech founders.
Cerespectus was co-founded by Bryan Pukenas, MD, Associate Professor of Radiology in Penn Medicine.
MavriX will initiate a clinical trial of a gene therapy for Angelman syndrome.
Capstan Therapeutics, a biotechnology company spun out of Penn, has initiated its Phase 1 trial of an in vivo CAR-T therapy.
REGENXBIO was co-founded by James M. Wilson, MD, PhD, the Rose H. Weiss Orphan Disease Center Director's Professor in Penn Medicine.
Vivodyne was co-founded by Dan Huh, PhD, Professor of Bioengineering in Penn Engineering and CEO Andrei Georgescu.,
Penn has over 5,000 research faculty spanning 200+ centers.
The 2025 Global Startup Ecosystem Report has been released.
Melissa Kelly, PhD, Deputy Managing Director of PCI, served as a panelist and shared her insights on the impact of AI.